Open AccessTime‐Limited Triplet Therapy Induces Rapid Undetectable MRD Responses in CLL
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2020-0558
Subject(s) - venetoclax , medicine , obinutuzumab , minimal residual disease , chronic lymphocytic leukemia , oncology , ibrutinib , leukemia
Zanubrutinib, obinutuzumab, and venetoclax (BOVen), given on a treatment schedule driven by minimal residual disease milestones, is a promising approach to previously untreated chronic lymphocytic leukemia, according to new findings from an investigator‐initiated phase II study.